Blockchain Registration Transaction Record

NanoViricides to Launch Phase II Ebola Trial of Oral NV-387 in DRC

NanoViricides to start Phase II trial of oral NV-387 for Ebola in DRC. The broad-spectrum antiviral could offer a simpler treatment option amid an outbreak.

The launch of this Phase II trial represents a critical step in the fight against Ebola, particularly the Bundibugyo strain, which is currently causing an expanding outbreak in the DRC. If successful, NV-387 Oral Gummies could provide a much-needed oral treatment option that is easier to administer in resource-limited settings than current infusion-based therapies. This could significantly improve patient access and outbreak response. Moreover, the broad-spectrum nature of NV-387 suggests potential against other viral threats, including RSV, COVID, and influenza. Investors and public health officials alike should watch this trial closely, as positive results could validate NanoViricides' nanoviricide platform and open doors to multiple antiviral applications.